LATEST NEWS   Gov't must wisely maintain diplomatic ties with all nations, enhance strategic cooperation to address regional and border issues - King | Malaysia will remain strong through the spirit of close collaboration between the federal and state governments - King | Malaysia should remain firm in upholding peace and opposing terrorism and oppression - King | King wants the government to continue supporting smallholders, farmers, breeders, and fishermen, and to proactively strengthen the agriculture sector, commodities, and the food supply chain. | Malaysia must demonstrate its capability in leading and shaping ASEAN’s direction - King | 

Kolmar BNH Strives For Global Expansions Building On HemoHim's Recognition

KUALA LUMPUR, Oct 22 (Bernama) -- Kolmar BNH immune-boosting health supplement, ‘HemoHim’, has earned international recognition for its quality from both the United States (US) Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), enhancing its credibility in the global marketplace.

In a statement, Kolmar BNH announced its Sejong plant obtained a No Action Indicated (NAI) classification following an inspection by the US FDA in September.

This classification, which confirms that the facility fully complies with US Current Good Manufacturing Practice (cGMP) standards for quality control, has further intensified Kolmar BNH’s competitiveness as a leading global Original Development Manufacturer (ODM) in the health supplement industry.

“We are committed to enhancing our competitiveness in global markets through ongoing quality innovation and additional global certifications, with HemoHim at the forefront of our efforts,” said an official from Kolmar BNH.

The FDA inspection was conducted to evaluate the company’s quality management capabilities, particularly in response to the increasing exports of HemoHim to the US.

The NAI classification reflects a comprehensive evaluation of key factors, including manufacturing processes, hygiene standards, quality control procedures, and employee training.

Meanwhile, HemoHim’s quality has previously been recognised in Australia, where the Sejong plant obtained Good Manufacturing Practice (GMP) certification from the TGA in 2021.

To meet the Australian TGA’s GMP standards, Kolmar BNH implemented a Standard Operating Procedure (SOP) at the Sejong plant that aligns with international GMP guidelines for pharmaceutical production and quality control.

Building on its success with FDA and TGA certifications, Kolmar BNH plans to expedite HemoHim's expansion into global markets.

Launched in 2006 and distributed by Atomy, HemoHim is Korea’s first individually approved immune-boosting supplement, made from Korean natural ingredients, with the product currently exported to approximately 20 countries.

-- BERNAMA